Results
1 -
10 of
23The Use of Pediatric Patient-Derived Xenografts for Identifying Novel Agents and Combinations, Patient-Derived Mouse Models of Cancer Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer, npj Breast Cancer Identifying novel therapeutic agents using xenograft models of pediatric cancer, Cancer Chemotherapy and Pharmacology Classification of PARP Inhibitors Based on PARP Trapping and Catalytic Inhibition, and Rationale for Combinations with Topoisomerase I Inhibitors and Alkylating Agents, PARP Inhibitors for Cancer Therapy Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?, La radiologia medica Medical Management of Breast Cancer in BRCA Mutation Carriers, Managing BRCA Mutation Carriers BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer, Translational Research in Breast Cancer Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations, Cancer Chemotherapy and Pharmacology Die klonale Evolution des Osteosarkoms, Der Pathologe Targeting DNA repair and replication stress in the treatment of ovarian cancer, International Journal of Clinical Oncology